Clinical experiment designed to assess clinical efficacy targeting AAV in human. Primary outcome: Validate AAV-LRRK2 IND-Enabling Study Design
Description
AAV-LRRK2 IND-Enabling Study Design
Background and Rationale
This IND-enabling study represents a critical translational milestone for AAV-mediated LRRK2 gene therapy in Parkinson's disease, building upon successful AAV serotype comparison studies. LRRK2 (Leucine-rich repeat kinase 2) mutations account for approximately 5-15% of familial Parkinson's cases and represent a validated therapeutic target. The study aims to generate comprehensive preclinical safety, biodistribution, and efficacy data required for FDA Investigational New Drug (IND) application submission. The experimental design encompasses Good Laboratory Practice (GLP)-compliant studies using the optimal AAV serotype identified from previous comparative analyses, likely AAV-PHP.eB or AAV9 variants with enhanced CNS tropism. Key components include dose-escalation toxicology studies in non-human primates, comprehensive biodistribution analysis across tissues, immunogenicity assessment, and pharmacokinetic/pharmacodynamic modeling. The study will evaluate both wild-type LRRK2 supplementation for loss-of-function mutations and dominant-negative approaches for gain-of-function variants like G2019S....
AAV-LRRK2 IND-Enabling Study Design
Background and Rationale
This IND-enabling study represents a critical translational milestone for AAV-mediated LRRK2 gene therapy in Parkinson's disease, building upon successful AAV serotype comparison studies. LRRK2 (Leucine-rich repeat kinase 2) mutations account for approximately 5-15% of familial Parkinson's cases and represent a validated therapeutic target. The study aims to generate comprehensive preclinical safety, biodistribution, and efficacy data required for FDA Investigational New Drug (IND) application submission. The experimental design encompasses Good Laboratory Practice (GLP)-compliant studies using the optimal AAV serotype identified from previous comparative analyses, likely AAV-PHP.eB or AAV9 variants with enhanced CNS tropism. Key components include dose-escalation toxicology studies in non-human primates, comprehensive biodistribution analysis across tissues, immunogenicity assessment, and pharmacokinetic/pharmacodynamic modeling. The study will evaluate both wild-type LRRK2 supplementation for loss-of-function mutations and dominant-negative approaches for gain-of-function variants like G2019S. Critical measurements include vector genome copy quantification, transgene expression levels, dopaminergic neuron preservation, motor function assessments, and comprehensive safety biomarkers. Innovation lies in the targeted approach to LRRK2-associated Parkinson's disease, representing a precision medicine strategy for genetically-defined patient populations. The study design incorporates advanced analytical methods including single-cell RNA sequencing, proteomics, and advanced imaging techniques to comprehensively characterize therapeutic effects and potential off-target activities. Significance extends beyond individual patient benefit to establishing regulatory precedent for AAV-based neurodegeneration therapies and providing a roadmap for subsequent gene therapy programs targeting familial Parkinson's disease variants.
This experiment directly tests predictions arising from the following hypotheses:
Partial Neuronal Reprogramming via Modified Yamanaka Cocktail
Synthetic Biology Rewiring via Orthogonal Receptors
RAB27A-dependent extracellular vesicle engineering for mitochondrial cargo delivery
CX43 hemichannel engineering enables size-selective mitochondrial transfer
Experimental Protocol
Phase 1: GLP Toxicology Studies (Months 1-6) - Conduct dose-escalation studies in 48 cynomolgus macaques (n=8 per group, 6 dose levels) via intrathecal or intraventricular AAV-LRRK2 administration. Doses: 1×10^11, 3×10^11, 1×10^12, 3×10^12, 1×10^13, 3×10^13 vg/animal. Phase 2: Biodistribution Analysis (Months 2-8) - Quantify vector distribution in CNS and peripheral tissues using qPCR at 4, 12, and 24 weeks post-injection in 36 animals (n=6 per timepoint per dose group). Phase 3: Immunogenicity Assessment (Months 1-12) - Monitor AAV capsid and LRRK2 transgene-specific immune responses via ELISA, ELISpot, and neutralizing antibody assays in all animals at baseline, 2, 4, 8, 12, 24, and 48 weeks. Phase 4: Efficacy Studies (Months 6-18) - Evaluate motor function using automated gait analysis, rotarod performance, and fine motor tasks in MPTP-lesioned macaques treated with therapeutic doses. Assess dopaminergic neuron preservation via PET imaging and post-mortem immunohistochemistry. Phase 5: Analytical Development (Months 1-24) - Develop and validate GMP-compatible analytical assays for vector potency, purity, and identity testing. Establish release criteria and stability protocols for clinical-grade AAV-LRRK2 product. All studies follow FDA guidelines for gene therapy IND applications with continuous safety monitoring and predetermined stopping criteria.
Expected Outcomes
Establish Maximum Tolerated Dose (MTD) at 3×10^12 vg with dose-limiting toxicity observed at 1×10^13 vg, characterized by inflammatory cell infiltration and behavioral changes in ≥2 animals
Demonstrate CNS-restricted biodistribution with >90% vector genomes localized to brain and spinal cord tissues, <5% peripheral organ distribution, and preferential targeting of dopaminergic neurons
Achieve therapeutic LRRK2 expression levels (2-5 fold endogenous) in substantia nigra and striatum, maintained for ≥24 weeks with <20% inter-animal variability
Show 60-80% preservation of dopaminergic neurons compared to vehicle controls in MPTP lesion model, with significant improvement in motor function scores (p<0.01)
Document manageable immunogenicity profile with <30% animals developing neutralizing antibodies at therapeutic doses, no severe immune-mediated adverse events
Generate comprehensive IND-ready documentation package including investigator brochure, clinical protocol framework, and manufacturing information meeting FDA requirements
Success Criteria
• No severe adverse events or deaths attributed to AAV-LRRK2 at proposed clinical starting dose (1×10^11 vg)
• Vector biodistribution shows ≥80% CNS localization with minimal off-target organ accumulation (<10% total dose)
• Therapeutic transgene expression achieved in ≥70% of target dopaminergic neurons with duration >6 months
• Significant neuroprotective effect demonstrated with ≥50% reduction in neurodegeneration compared to controls (p<0.05)
• Immunogenicity profile deemed acceptable by FDA standards with reversible responses and no autoimmune complications
• Successful FDA pre-IND meeting with agency agreement on clinical trial design and no major regulatory objections raised
Phase 1: GLP Toxicology Studies (Months 1-6) - Conduct dose-escalation studies in 48 cynomolgus macaques (n=8 per group, 6 dose levels) via intrathecal or intraventricular AAV-LRRK2 administration. Doses: 1×10^11, 3×10^11, 1×10^12, 3×10^12, 1×10^13, 3×10^13 vg/animal. Phase 2: Biodistribution Analysis (Months 2-8) - Quantify vector distribution in CNS and peripheral tissues using qPCR at 4, 12, and 24 weeks post-injection in 36 animals (n=6 per timepoint per dose group). Phase 3: Immunogenicity Assessment (Months 1-12) - Monitor AAV capsid and LRRK2 transgene-specific immune responses via ELISA, ELISpot, and neutralizing antibody assays in all animals at baseline, 2, 4, 8, 12, 24, and 48 weeks.
...
Phase 1: GLP Toxicology Studies (Months 1-6) - Conduct dose-escalation studies in 48 cynomolgus macaques (n=8 per group, 6 dose levels) via intrathecal or intraventricular AAV-LRRK2 administration. Doses: 1×10^11, 3×10^11, 1×10^12, 3×10^12, 1×10^13, 3×10^13 vg/animal. Phase 2: Biodistribution Analysis (Months 2-8) - Quantify vector distribution in CNS and peripheral tissues using qPCR at 4, 12, and 24 weeks post-injection in 36 animals (n=6 per timepoint per dose group). Phase 3: Immunogenicity Assessment (Months 1-12) - Monitor AAV capsid and LRRK2 transgene-specific immune responses via ELISA, ELISpot, and neutralizing antibody assays in all animals at baseline, 2, 4, 8, 12, 24, and 48 weeks. Phase 4: Efficacy Studies (Months 6-18) - Evaluate motor function using automated gait analysis, rotarod performance, and fine motor tasks in MPTP-lesioned macaques treated with therapeutic doses. Assess dopaminergic neuron preservation via PET imaging and post-mortem immunohistochemistry. Phase 5: Analytical Development (Months 1-24) - Develop and validate GMP-compatible analytical assays for vector potency, purity, and identity testing. Establish release criteria and stability protocols for clinical-grade AAV-LRRK2 product. All studies follow FDA guidelines for gene therapy IND applications with continuous safety monitoring and predetermined stopping criteria.
Expected Outcomes
Establish Maximum Tolerated Dose (MTD) at 3×10^12 vg with dose-limiting toxicity observed at 1×10^13 vg, characterized by inflammatory cell infiltration and behavioral changes in ≥2 animals
Demonstrate CNS-restricted biodistribution with >90% vector genomes localized to brain and spinal cord tissues, <5% peripheral organ distribution, and preferential targeting of dopaminergic neurons
Achieve therapeutic LRRK2 expression levels (2-5 fold endogenous) in substantia nigra and striatum, maintained for ≥24 weeks with <20% inter-animal variability
Show 60-80% preservation of dopaminergic neur
...
Establish Maximum Tolerated Dose (MTD) at 3×10^12 vg with dose-limiting toxicity observed at 1×10^13 vg, characterized by inflammatory cell infiltration and behavioral changes in ≥2 animals
Demonstrate CNS-restricted biodistribution with >90% vector genomes localized to brain and spinal cord tissues, <5% peripheral organ distribution, and preferential targeting of dopaminergic neurons
Achieve therapeutic LRRK2 expression levels (2-5 fold endogenous) in substantia nigra and striatum, maintained for ≥24 weeks with <20% inter-animal variability
Show 60-80% preservation of dopaminergic neurons compared to vehicle controls in MPTP lesion model, with significant improvement in motor function scores (p<0.01)
Document manageable immunogenicity profile with <30% animals developing neutralizing antibodies at therapeutic doses, no severe immune-mediated adverse events
Generate comprehensive IND-ready documentation package including investigator brochure, clinical protocol framework, and manufacturing information meeting FDA requirements
Success Criteria
• No severe adverse events or deaths attributed to AAV-LRRK2 at proposed clinical starting dose (1×10^11 vg)
• Vector biodistribution shows ≥80% CNS localization with minimal off-target organ accumulation (<10% total dose)
• Therapeutic transgene expression achieved in ≥70% of target dopaminergic neurons with duration >6 months
• Significant neuroprotective effect demonstrated with ≥50% reduction in neurodegeneration compared to controls (p<0.05)
• Immunogenicity profile deemed acceptable by FDA standards with reversible responses and no autoimmune complications
• Successful FDA pre
...
• No severe adverse events or deaths attributed to AAV-LRRK2 at proposed clinical starting dose (1×10^11 vg)
• Vector biodistribution shows ≥80% CNS localization with minimal off-target organ accumulation (<10% total dose)
• Therapeutic transgene expression achieved in ≥70% of target dopaminergic neurons with duration >6 months
• Significant neuroprotective effect demonstrated with ≥50% reduction in neurodegeneration compared to controls (p<0.05)
• Immunogenicity profile deemed acceptable by FDA standards with reversible responses and no autoimmune complications
• Successful FDA pre-IND meeting with agency agreement on clinical trial design and no major regulatory objections raised